Pantoprazole sodium hydrate

CAS No. 164579-32-2

Pantoprazole sodium hydrate( SKF-96022 sodium hydrate )

Catalog No. M12511 CAS No. 164579-32-2

A proton pump inhibitor that inhibits gastric acid secretion; works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 27 In Stock
100MG 42 In Stock
200MG 65 In Stock
500MG 132 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Pantoprazole sodium hydrate
  • Note
    Research use only, not for human use.
  • Brief Description
    A proton pump inhibitor that inhibits gastric acid secretion; works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.
  • Description
    A proton pump inhibitor that inhibits gastric acid secretion; works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid; inhibits autophagy and increases the toxicity of docetaxel in vitro and in vivo.Ulcer Approved.
  • In Vitro
    Pantoprazole sodium hydrate (BY1023 sodium hydrate; 1-10000 μM) leads to concentration-dependent increases in endosomal pH in EMT-6 and MCF7 cells.Pantoprazole sodium hydrate can block exosome release. Pantoprazole sodium hydrate inhibits the activity of V-H+-ATPase and impaires the ability of tumour cells (melanomas, adenocarcinomas, and lymphoma cell lines) to acidify the extracellular medium.
  • In Vivo
    Pantoprazole sodium hydrate (BY1023 sodium hydrate; 200 mg/kg; IP; once a week for 3 weeks) significantly increases tumor growth delay of MCF-7 xenografts combined with Doxorubicin. Pantoprazole sodium hydrate (0.3-3 mg/kg, p.o.) dose-dependently decreases both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats. Animal Model:Mice bearing MCF-7 or A431 xenografts Dosage:200 mg/kg Administration:IP; once a week for 3 weeks; alone or 2 hours before Doxorubicin (6 mg/kg i.v.)Result:Showed even greater growth delay of MCF-7 xenografts with Doxorubicin compared with the single-dose combination. Significantly increased tumor growth delay with a single dose with Doxorubicin.
  • Synonyms
    SKF-96022 sodium hydrate
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    Proton Pump
  • Recptor
    Potassium-transportingATPase|Protonpump
  • Research Area
    Other Indications
  • Indication
    Ulcer

Chemical Information

  • CAS Number
    164579-32-2
  • Formula Weight
    433.38
  • Molecular Formula
    C16H15F2N3O4S . 3/2H2 O . Na
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in H2O
  • SMILES
    O.O.O.[Na+].[Na+].COC1=C(OC)C(CS(=O)C2=NC3=C([N-]2)C=CC(OC(F)F)=C3)=NC=C1.COC1=C(OC)C(CS(=O)C2=NC3=C([N-]2)C=CC(OC(F)F)=C3)=NC=C1
  • Chemical Name
    1H-Benzimidazole, 6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-, sodium salt, hydrate (2:2:3)

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Tan Q, et al. Br J Cancer. 2015 Mar 3;112(5):832-40. 2. Feng S, et al. Oncol Rep. 2016 Dec;36(6):3207-3214. 3. Zeng X, et al. Oncotarget. 2016 Apr 19;7(16):22460-73.
molnova catalog
related products
  • Ilaprazole sodium

    Ilaprazole is a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity.

  • Lansoprazole sodium

    Lansoprazole sodium is a proton pump inhibitor (PPI) and a potent inhibitor of gastric acidity which is widely used in the therapy of gastroesophageal reflux and peptic ulcer disease.

  • Esomeprazole

    Esomeprazole is the S-isomer of omeprazole, inhibits the lysosomal cysteine protease legumain to prevent cancer metastasis.